Nasdaq GlobeNewswire

Oxford Immunotec Reports Third Quarter 2017 Financial Results

  • Third quarter revenue of $30.4 million, an increase of 17% compared to prior year period
  • Continued growth from both the Tuberculosis (TB) and Tick-borne disease franchises, with double-digit revenue growth in all three geographies served
  • Gross margin improved by 450 basis points on a sequential basis, driven by strong progress in TB margins

OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced third quarter 2017 financial results.

"We are pleased to report another strong quarter, with solid growth across both franchises and all three geographies served," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "As we move forward through the remainder of the year and into 2018, we will continue to focus on driving revenue growth and progressing the company towards profitability."

By revenue type, total revenues were, in millions:

  Three Months Ended September 30,
   2017    2016   Percent
Product $   12.0   $   9.7   24 %
Service     18.4       16.4   12 %
Total Revenue $   30.4   $   26.1   17 %

By indication, total revenues were, in millions:

  Three Months Ended September 30,
   2017    2016   Percent
Tuberculosis $   24.4   $   22.0   11 %
Tick-Borne Disease and Other     6.0       4.1   45 %
Total Revenue $   30.4   $   26.1   17 %

By geography, total revenues were, in millions:

  Three Months Ended September 30,
          Percent Change
   2017    2016   As Reported   Constant
United States $   18.8   $   16.2   16 %   16 %
Europe & ROW   2.2       1.7   26 %   22 %
Asia     9.4       8.2   15 %   18 %
Total Revenue $   30.4   $    26.1   17 %   17 %

(1) Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure "constant currency basis" in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. We consider the use of a period over period revenue comparison on a constant currency basis to be helpful to investors, as it provides a revenue growth measure free of positive or negative volatility due to currency fluctuations.

Third Quarter 2017 Financial Results

Revenue for the third quarter of 2017 was $30.4 million, representing 17% growth over third quarter 2016 revenue of $26.1 million. On a constant currency basis, revenue growth was also 17% versus the prior year period. Tuberculosis revenue for the third quarter of $24.4 million increased 11% over the prior year period.

2017 third quarter product revenue was $12.0 million, representing a 24% increase from product revenue of $9.7 million in the third quarter of 2016. The increase was primarily driven by sales of tick-borne disease kits, as well as growth in Asia and Europe & ROW. Service revenue for the third quarter of 2017 was $18.4 million, up 12% from 2016 third quarter revenue of $16.4 million. The increase in service revenue was primarily driven by strong growth in our tick-borne disease business, as well as tuberculosis volume increases in the United States.

United States revenue was $18.8 million in the third quarter of 2017, representing 16% growth over revenue of $16.2 million in the prior year period. The increase was due to growth in our tuberculosis and tick-borne disease businesses.

Europe & ROW revenue was $2.2 million in the third quarter of 2017, representing a 26% increase compared to the third quarter of 2016. On a constant currency basis, Europe & ROW increased 22% versus the third quarter of 2016. The increase was primarily due to tuberculosis growth in the UK and continental European markets, as well as sales of tick-borne disease kits.

Asia revenue was $9.4 million in the third quarter of 2017, representing an increase of 15% over 2016 third quarter revenue of $8.2 million. On a constant currency basis, Asia increased 18% versus the third quarter of 2016. The increase was primarily due to the timing of orders and higher sales in South Korea.

Gross profit for the third quarter of 2017 was $17.3 million, an increase of $2.7 million over gross profit of $14.6 million in the same period of 2016. Gross margin was 56.7%, an increase of 80 basis points from gross margin of 55.9% in the third quarter of 2016. The third quarter gross margin performance reflects lower royalty expenses due to the June 2017 Statens Serum Institut settlement, an underlying improvement in TB margins, and favorable mix, offset by higher volumes in our tick-borne disease business, which carries lower gross margins, as well as some early infrastructure investments necessary to meet future growth.

Operating expenses were $32.5 million in the third quarter of 2017, an increase of $13.6 million compared to $18.9 million in the same period last year. The increase in operating expenses was largely due to the inclusion of a one-time non-cash impairment charge of $11.1 million to write-off certain intangible assets acquired in conjunction with the 2016 acquisition of Imugen, as well as expenses related to our BLA submissions and ongoing patent litigation. In the third quarter, we also recorded a credit of $880,000 related to the change in fair value of contingent consideration associated with the acquisition of Immunetics.

Net loss for the third quarter of 2017 was $16.9 million, or $0.70 per share, compared to $4.0 million, or $0.18 per share, in the third quarter of 2016. Net loss per share was based on 24,123,574 and 22,365,349 weighted average ordinary shares outstanding for the third quarters of 2017 and 2016, respectively.

EBITDA for the third quarter was $(14.7) million compared to $(3.0) million in the third quarter of 2016. Adjusted EBITDA for the third quarter of 2017 was $(2.5) million compared to $(2.2) million in the same period in 2016. Both EBITDA and Adjusted EBITDA are non-GAAP measures.

Business Outlook

We expect to report revenue of between $25.4 and $26.4 million for the fourth quarter of 2017.

We now expect to report full year 2017 revenue of between $103.5 and $104.5 million, representing 20% - 21% year-over-year growth. We expect revenue to increase approximately 21% to 22% for the year using constant exchange rates. This compares to prior revenue guidance of between $103 and $106 million.

Conference Call

Oxford Immunotec will host a conference call on Tuesday, October 31, 2017 at 8:00 a.m. Eastern Time to discuss its third quarter 2017 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 99539511 approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at The replay will be available on the Company's website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions.  The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection.  The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics.  Also obtained through these acquisitions is the Company's third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA licensure.  The Company's fourth product line is focused on the transplantation market.  The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.  Additional information can be found at

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.  Immunetics is a trademark of Immunetics, Inc.

Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, intentions, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company's business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the "Risk Factors" section in our filings with the Securities and Exchange Commission ("SEC"). Our filings are available for free by visiting the investor section of our website,, or the SEC's website,

Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.


For Media and Investor Inquiries: 
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377

Oxford Immunotec Global PLC
Condensed consolidated statements of operations
    Three months ended September 30,   Nine months ended September 30,
(in thousands, except share and per share data)     2017       2016       2017       2016  
Product   $   12,000     $   9,713     $   30,808     $   27,144  
Service       18,429         16,396         47,246         35,229  
Total revenue       30,429         26,109         78,054         62,373  
Cost of revenue                
Product       4,027         3,616         11,366         10,421  
Service       9,141         7,887         24,791         17,853  
Total cost of revenue       13,168         11,503         36,157         28,274  
Gross profit       17,261         14,606       41,897       34,099  
Operating expenses:                
Research and development       4,467         3,532         12,220         9,837  
Sales and marketing       9,493         8,794         29,174         26,665  
General and administrative       8,141         6,466         23,007         16,200  
Change in fair value of contingent purchase price consideration       (880 )       60         (3,475 )       172  
Intangible assets impairment charges       11,064         -         11,064         -  
Settlement expense       196         -         9,831         -  
Total operating expenses       32,481         18,852         81,821         52,874  
Loss from operations       (15,220 )       (4,246 )       (39,924 )       (18,775 )
Other income (expense):                
Interest expense, net       (781 )       (54 )       (2,411 )       (88 )
Foreign exchange (losses) gains       (624 )       470         (1,277 )       1,707  
Other expense       -         (106 )       (262 )       (243 )
Loss before income taxes       (16,625 )       (3,936 )       (43,874 )       (17,399 )
Income tax (expense) benefit       (222 )       (60 )       2,189         (92 )
Net loss   $   (16,847 )   $   (3,996 )   $   (41,685 )   $   (17,491 )
Net loss per ordinary share-basic and diluted   $   (0.70 )   $   (0.18 )   $   (1.80 )   $   (0.78 )
Weighted-average shares used to compute net loss per ordinary share-basic and diluted       24,123,574         22,365,349         23,159,986         22,333,911  

Reconciliation of net loss to Adjusted EBITDA (1)
    Three months ended September 30,   Nine months ended September 30,
(in thousands)     2017       2016       2017       2016  
Net loss   $   (16,847 )   $   (3,996 )   $   (41,685 )   $   (17,491 )
Income tax expense (benefit)       222         60         (2,189 )       92  
Interest expense, net       641         54         1,982         88  
Depreciation and amortization of intangible assets       1,122         862         3,115         2,067  
Accretion and amortization of loan fees       140         -         429         -  
EBITDA       (14,722 )       (3,020 )     (38,348 )       (15,244 )
Reconciling items:                
Share-based compensation expense       1,506         1,368         4,266         3,827  
Unrealized exchange losses (gains)       333         (572 )       614         (1,990 )
Change in fair value of contingent purchase price consideration       (880 )       60         (3,475 )       172  
Intangible assets impairment charges       11,064         -         11,064         -  
Settlement expense       196         -         9,831         -  
Adjusted EBITDA   $   (2,503 )   $   (2,164 )   $   (16,048 )   $   (13,235 )

(1) EBITDA and Adjusted EBITDA are non-GAAP measures that we calculate as net loss, adjusted for the impact of earnings or charges resulting from matters that we consider not to be indicative of our ongoing operations. We believe that these measures provide useful information to investors in understanding and evaluating our operating results in the same manner as our management and Board of Directors. Our presentation of these measures is not made in accordance with U.S. GAAP, and our computation of these measures may vary from others in the industry. Our use of these measures has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP.

The above table presents a reconciliation of net loss, the most comparable U.S. GAAP measure, to EBITDA and Adjusted EBITDA for each of the periods indicated.

Oxford Immunotec Global PLC
Condensed consolidated balance sheets
    September 30,   December 31,
(in thousands, except share and per share data)     2017       2016  
Current assets:        
Cash and cash equivalents   $   67,743     $   59,110  
Accounts receivable, net       21,652         13,265  
Inventory, net       9,174         7,437  
Prepaid expenses and other assets       3,147         2,390  
Total current assets     101,716         82,202  
Restricted cash, non-current       200         200  
Property and equipment, net       8,927         7,793  
In-process research and development       6,970         16,170  
Goodwill       3,967         3,822  
Other intangible assets, net       8,296         11,017  
Deferred tax asset       6,725         2,630  
Other assets       190         178  
Total assets   $ 136,991     $ 124,012  
Liabilities and shareholders' equity        
Current liabilities:        
Accounts payable   $   3,141     $   3,201  
Accrued liabilities       15,563         14,282  
Settlement liability       2,396         -  
Contingent purchase price consideration       -         882  
Deferred income       345         41  
Current portion of loans payable       89         84  
Total current liabilities       21,534         18,490  
Long-term portion of loans payable       29,787         29,601  
Settlement liability       7,930         -  
Contingent purchase price consideration       -         2,593  
Other liabilities       364         364  
Total liabilities       59,615         51,048  
Shareholders' equity:        
Ordinary shares, £0.006705 nominal value; 36,183,293 shares authorized at September 30, 2017 and December 31, 2016, and 25,596,345 and 22,635,431 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively       269         243  
Additional paid-in capital     292,959       249,128  
Accumulated deficit     (210,341 )     (168,656 )
Accumulated other comprehensive loss       (5,511 )       (7,751 )
Total shareholders' equity       77,376         72,964  
Total liabilities and shareholders' equity   $ 136,991     $ 124,012  

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Elite Petro & Gas, a new brand by Elite Capital & Co. Limited15.10.2018 16:15Pressemelding

LONDON, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Today at Elite Petro & Gas headquarters in the City of London, Dr. Faisal Khazaal (Chairman) and Mr. George Matharu (President) announced the official launch of this new Division within Elite Capital & Co. Limited, which was setup to provide Finance, Trading and Advisory services in the global Oil and Gas markets. “Elite Petro & Gas is a Finance, Trading and Advisory firm with a focus on downstream activities in the global Oil and Gas markets. We are a results-driven business, working closely with our clients to deliver tangible solutions and outcomes.” Mr. George Matharu, President of Elite Petro & Gas, said. The oil and gas industry is facing challenging times, particularly from changes in the political landscape and increased price volatility. Understanding the nuances of working internationally, often in emerging economies and less stable regimes, is key to ensuring that business risks are appropriately managed. The Elite Petro & Gas (“EPG”

Prof. Dr. C. Oliver Kappe is awarded the 2018 IUPAC-ThalesNano Prize for Flow Chemistry15.10.2018 16:08Pressemelding

KARLSRUHE, Germany and BUDAPEST, Hungary and GRAZ, Austria, Oct. 15, 2018 (GLOBE NEWSWIRE) -- The 2018 IUPAC-ThalesNano prize has been awarded to Professor C. Oliver Kappe. The prize will be presented at the 15th International Conference on Microreaction Technology (IMRET15) in Karlsruhe on October 21, 2018. The award address will be delivered at the Flow Chemistry Europe Conference in Cambridge, UK on February 26th, 2019. The prize consists of an award of $10,000 US Dollars. Professor Kappe is Professor of Chemistry at the University of Graz (Austria) and Scientific Director for Continuous Flow Synthesis and Processing (CC Flow) at the Research Center Pharmaceutical Engineering GmbH (RCPE). Professor Kappe has over 400 publications in the areas of continuous flow chemistry, application of microreactors, process intensification, and microwave-assisted reactions. He and his team have published syntheses with challenging systems and chemistry. He has served as an Ambassador for Flow Chem

Gunvor Closes Innovative US $745 Million Facility Linked to Sustainability Targets15.10.2018 12:00Pressemelding

Related savings will go to support new Gunvor Foundation GENEVA, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Gunvor Group (“Gunvor”) has closed an innovative US $745 million secured borrowing base facility (“Facility”) that includes performance commitments related to Gunvor’s sustainability targets. Gunvor is the first energy commodities trading company to close a financing in which the interest rate will be dependent on the company’s year-on-year improvements in areas such as transparency, governance and the environment. The Facility, originally launched at US $625 million in 2012, was a renewal to provide for the working capital requirements of the company’s Antwerp and Rotterdam refineries. It was significantly oversubscribed to US $745 million through the addition of new lenders. The Facility was arranged by ING Bank, who acted as sole Coordinator and Active Bookrunner while maintaining its roles as Security Agent, Facility Agent and Fronting Bank. The structure for the sustainability target

Nasdaq Launches ESG futures in the Nordics15.10.2018 10:00Pressemelding

STOCKHOLM, Sweden, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the launch of futures based on the recently launched OMXS30 ESG Responsible index (OMXS30ESG). The product is the first exchange listed and ESG compliant index future in the world. “In recent years we have seen institutions increase efforts to integrate sustainability into their investment strategies, with the Nordic region being in the forefront of this trend,” says Alessandro Romani, Head of European Equity Derivatives at Nasdaq. “Those looking to invest in a more sustainable way need more investment products based on established and liquid indexes. Our existing OMXS30 index future contract is among the most traded in Europe and we expect to see the same interest for the ESG version.” The OMXS30ESG Index was developed in cooperation with a number of leading Nordic asset managers, including Swedbank Robur. “At Swedbank, innovation and constant development are an important part of the business, a

Telix and ANMI Expand PSMA Imaging Partnership15.10.2018 00:00Pressemelding

MELBOURNE, Australia and LIÈGE, Belgium, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), today announced that it has expanded its partnership with Advanced Nuclear Medicine Ingredients SA (“ANMI”) for the 68Ga-HBED-CC-PSMA-11 (68Ga-PSMA) cold kit. The 68Ga-PSMA kit is developed by ANMI and commercialized by Telix for the US market where it is marketed as illumetTM . In response to considerable clinical interest in the illumetTM product, Telix has commenced scale-up manufacturing in the United States, following the recent filing of a drug master file (DMF) and the launch of several major clinical trials using the product, including the 750 patient VISION phase III trial (Endocyte, Inc.) and a 500-patient phase II study at Memorial Sloan Kettering C

Brookfield Asset Management 2018 Third Quarter Results Conference Call And Webcast12.10.2018 15:33Pressemelding

Date: Thursday, November 8, 2018 Time: 11:00 a.m. (Eastern Time) BROOKFIELD, NEWS, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management (NYSE:BAM)(TSX:BAM.A)(EURONEXT AMSTERDAM:BAMA): Third Quarter Conference Call You are invited to participate in Brookfield Asset Management’s 2018 Third Quarter Conference Call & Webcast on Thursday, November 8, 2018 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on November 8th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at “News – Press Releases.” The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial (877) 255-3077 toll free in North America, or for overseas calls please dial (647) 252-4453 at approximately 10:50 a.m. The Conference Call will also be Webcast live at htt

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom